TaleeBio founder Dr. Michael Welsh was awarded the 2018 Warren Alpert Foundation Prize for his transformative discoveries in cystic fibrosis. In association with Harvard Medical School, the Warran Alpert Foundation recognizes leading researchers whose work has improved the understanding, prevention, treatment or cure for human disease.
Talee Bio wins 2018 PACT Enterprise Award for best healthcare startup. The 25th annual gathering celebrated leaders in Philadelphia’s healthcare and space.
MHV portfolio company, Tmunity, raises large A round to progress a promising pipeline of T-cell immunotherapies.
See coverage in FierceBiotech:
May 25th, 2017 – Militia Hill Ventures portfolio company, Talee Bio, gets covered in Philadelphia Business Journal.
October 6th, 2016 – Militia Hill Ventures portfolio company, Immunome, gets covered in FierceBiotech with its recent $12.2 million in additional series A financing.
August 29th, 2016 – Jane Hollingsworth, Founding Managing Partner of Militia Hill Ventures, and other life science industry leaders gathered in Philadelphia on Wednesday August 17th, 2016 to ask Pennsylvania state officials to enhance existing programs, and establish new policies and initiatives to make Pennsylvania more competitive in the biopharmaceutical and medical device sector.
More information can be found at:
March 17th, 2016 – Militia Hill Ventures is pleased to announce that it has been selected by the University City Science Center to be the preferred commercialization partner for Phase 1 Ventures Program. Phase 1 Ventures is a startup accelerator for “long horizon” technologies – those requiring significant development and/or regulatory approvals – such as healthcare, materials, or energy companies. Phase 1 Ventures initially provides up to $25,000 in support and a host of resources, including substantial services, to help get the company going. Companies in the program then focus on building commercialization plans and applying for non-dilutive funding such as SBIR or STTR grants. For companies that are successful at securing grants, Phase 1 Ventures could provide up to an additional $450,000 in financing.
“Promising technology is a great first step, but it is not sufficient for a company to be investible,” says Jane Hollingsworth, Managing Partner of Militia Hill Ventures, and former CEO of NuPathe. “Too many companies built around promising technologies fail because they lack experienced management. Phase 1 Ventures and Militia Hill Ventures aim to provide this critical advantage to companies, giving them a much better opportunity to attract investment and achieve ultimate success.”
More information can be found at:
March 7th, 2016 – Last week, Drexel and Brandywine Real Estate announced the development of Schuylkill Yards, an integrated urban environment, offering a collaborative and connected community made up of educational and medical institutions, businesses, residents and visitors bound together by the pursuit of innovation.
The gateway of Schuylkill Yards is located at 3001 Market Street, the current offices of Militia Hill Ventures and the MHV Innovation Hub. Jane Hollingsworth, Managing Partner of Militia Hill Ventures said, “We are thrilled to be included the continued renaissance of University City. The mission of the Schuylkill Yards project is to create next great urban innovation district. This aligns perfectly with Militia Hill Ventures mission to create and develop exceptional life sciences companies in the Philadelphia region.”
More information on the Schuylkill Yards development can be found below:
March 1, 2016 – Philadelphia, PA – Militia Hill Ventures, a firm dedicated to the creation and development of high-growth life sciences companies in Philadelphia, announced the opening of the MHV Innovation Hub at 3001 Market Street, across from Philadelphia’s 30th Street Station. Initial residents in the MHV Innovation Hub include biotechnology companies involved in the discovery and development of new therapies for patients with unmet medical need, companies focused on diagnostics and health outcomes, and life sciences investors.
Militia Hill Ventures is led by experienced entrepreneurs Jane Hollingsworth and Joan Lau. Ms. Hollingsworth was co-founder and former CEO of NuPathe Inc., a publicly-traded biopharmaceutical company focused on diseases of the central nervous system and sold to Teva Pharmaceuticals in 2014. She also co-founded and served as EVP of Auxilium Pharmaceuticals, a publicly-traded specialty pharmaceutical company and sold to Endo Pharmaceuticals. Dr. Lau was previously CEO of Locus Pharmaceuticals and subsequently Azelon Therapeutics, venture capital-funded companies focused on discovery and development of therapeutics in multiple disease areas.
Jane Hollingsworth, managing partner of Militia Hill Ventures said, “the opening of the MHV Innovation Hub is an important step in fulfilling our firm’s mission. It offers a central location in the midst of Philadelphia’s thriving medical research institutions and academic communities and provides the collaborative environment so helpful to building successful life sciences companies.”
“The local life sciences community is experiencing a rebirth and is poised to leverage the strong history of drug development and commercialization in the region,” added Joan Lau, managing partner of Militia Hill Ventures. “The MHV Innovation Hub resident companies exemplify and leverage this great regional strength, with veteran drug developers and entrepreneurs working together to invest in and grow the next generation of companies,” concluded Lau.
Michael Nutter, former Mayor of Philadelphia said, “While I was Mayor, it was important to me and my administration to spark innovation, including life science companies. The establishment of the MHV Innovation Hub is an important step forward in the City’s ongoing efforts to make Philadelphia a great center for the next generation of life-changing healthcare innovations and high-growth life sciences companies. Militia Hill Ventures has been, and continues to be at the forefront of this effort to maximize the value of the many great assets of our City.”
The MHV Innovation Hub currently provides offices, workstations, a café, locker facilities, conference rooms and many other advantages to its resident companies, with plans to add wet labs. The MHV Innovation Hub resident companies are able to utilize the shared space to convene conferences or educational offerings, hold board, investor or other meetings and host or participate in a variety of other industry-related activities. The MHV Innovation Hub is located together with PHL Next Stage Med, the new, Philadelphia-based health care company accelerator, and Plexus Innovation Hub, a medical device co-working community.
About Militia Hill Ventures
Militia Hill Ventures creates and develops transformative life sciences companies in the Philadelphia region. Through our broad network, relationships and domain expertise, we bring together cutting-edge scientific technology, world-class scientific experts, proven management and successful investors. This proactive approach generates companies capable of developing important new therapies for patients and delivering value to investors.
Founding Managing Partner
Militia Hill Ventures